Today we have reached an important milestone by demonstrating that our redesigned CardiaSense™ device showed excellent performance in a pre-clinical model at the Intervention Centre at Oslo University Hospital.
Over the last year we have significantly simplified manufacturing and added new important features to our system. Cardiaccs' team has eenworking together with our suppliers, Arrotek Medical Ltd and OSYPKA AG to reach this important goal.

We are happy to announce that Cardiaccs has been granted 9 MNOK by the Research Council of Norway for the AMPliSense project. The grant is provided as an Innovation project for the Industrial Sector (IPN) where Cardiaccs will work with Norner AS

Cardiaccs has been ISO 13485 certified for design and development of medical devices since 2016 and our successful renewal means that we are certified for a further three years.

As we approach commercialisation we can expect that surveillance by our Notified Body will become more rigourous and frequent requireing us to investment significant time and effort into maintaining our ISO 13485 certification and deliver products of the highest quality.

Watch as Cardiaccs CEO, Shane West, presents our history and aspirations to the distinguished audience at UiO Life Science conference.

Aleap member, Cardiaccs, received the happy news they are the recipients of €3M in EU funding through the Horizon 2020 Fast Track to Innovation program. The funds will be used to complete clinical trials and continue product development for Cardiaccs’ sensor for continuous measurement of cardiac function. Read article in DN (Norwegian)

Cardiaccs has conducted qualitative interviews with 20 cardiac surgeons in US and Germany. 70% of the surgeons spontaneously reacted positively when shown concept, all indicated that it would be advantageous in their current role. This confirms that we're heading in the right direction! Read full article

The first health incubator in Norway, Aleap, officially opened on October 12th. As a member of the incubator, Cardiaccs got the opportunity to present the Cardisense technology to the His Royal Highness Crownprince Haakon, the Norwegian Minister of Health and Care Services, Bent Høie, and the Governing Mayor of Oslo, Raymond Johansen. Read more

Today, the first patients have been enrolled in the clinical pilot study to evaluate the performance of Cardiaccs' temporary epicardial pace wire with integrated sensor, CardiaSense CS1, for continuous postoperative monitoring of myocardial function after heart surgery. The clinical pilot study will be conducted at Oslo University Hospital, Rikshospitalet in Norway and Aarhus University Hospital in Denmark.

Press release

Together with Høine AS and Skarpsinn Hau AS Cardiaccs proudly presents its new logo and visual profile. 

The €3M project supported by the EU H2020 funding initiative officially kicked off on Feb 28th at the Intervention Centre at Oslo University Hospital.

​

Cardiaccs, as the coordinator, was joined by project partners Aarhus University Hospital, Oslo Univerity Hospital, Osypka AG and German Heart Centre Berlin.

​

The program will accelerate development of our sensor system for intra and post operative monitoring of cardiac contractility. Follow the program on the SAMBAfun website and

Twitter

Come learn more about Cardiaccs as we pitch at the Oslo Life Science Conference on Feb 11th, and then at the Tekna Helseteknologikonferansen on Mar 19th. We are honoured and excited to have the opportunity to share our technology and progress with the healthcare community.

We are very pleased to announce the appointment of Mr. Shane West as Chief Executive Officer effective May 1st. Shane succeeds Prof. Erik Fosse who has been CEO since founding the company in 2009. Erik will continue to play a very active role in the company as Chairman of the Board of Directors. Read full press release here

We are very proud to have been selected to the Final of the DNB Healthcare Prize 2017. The Final of the DNB Healthcare Prize 2017 will take place at the DNB Nordic Healthcare Conference 2017 and Cardiaccs is one of six companies which will get the opportunity to win the first prize of 1 million NOK. Date: 14 December. Venue: DNB in Bjørvika, Dronning Eufemiasgate 30, 0191 Oslo

Cardisense has been approved for funding through the Eurostars programme. We are honoured and proud to have been ranked as number 20 out of 269 eligible applications from all over Europe